drugset / Trial / NCT03529266

Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.

NCT03529266 ↗

Phase 2 Completed 57 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer and gastroesophageal junction cancer.

Timeline

Start
2018-06-01
Primary completion
2019-03-31
Completion
2021-08-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Porcine Fibrin Sealant Unknown 2.5 ml —